Travere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of ($0.40), $0.17 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $127.2 million versus the consensus estimate of $137.34 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.